JP2006514104A - グリコーゲンシンターゼキナーゼ−３阻害剤 - Google Patents

グリコーゲンシンターゼキナーゼ−３阻害剤 Download PDF

Info

Publication number
JP2006514104A
JP2006514104A JP2005502348A JP2005502348A JP2006514104A JP 2006514104 A JP2006514104 A JP 2006514104A JP 2005502348 A JP2005502348 A JP 2005502348A JP 2005502348 A JP2005502348 A JP 2005502348A JP 2006514104 A JP2006514104 A JP 2006514104A
Authority
JP
Japan
Prior art keywords
acid
gsk
amino acid
residue
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2005502348A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006514104A5 (enExample
Inventor
ハジト エルダー‐フィンケルマン，
Original Assignee
テル アヴィヴ ユニヴァーシティ フューチャー テクノロジー ディヴェロップメント エル．ピー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by テル アヴィヴ ユニヴァーシティ フューチャー テクノロジー ディヴェロップメント エル．ピー． filed Critical テル アヴィヴ ユニヴァーシティ フューチャー テクノロジー ディヴェロップメント エル．ピー．
Publication of JP2006514104A publication Critical patent/JP2006514104A/ja
Publication of JP2006514104A5 publication Critical patent/JP2006514104A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Psychology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
JP2005502348A 2002-12-12 2003-12-11 グリコーゲンシンターゼキナーゼ−３阻害剤 Pending JP2006514104A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43264402P 2002-12-12 2002-12-12
US48271903P 2003-06-27 2003-06-27
PCT/IL2003/001057 WO2004052404A2 (en) 2002-12-12 2003-12-11 Glycogen synthase kinase-3 inhibitors

Publications (2)

Publication Number Publication Date
JP2006514104A true JP2006514104A (ja) 2006-04-27
JP2006514104A5 JP2006514104A5 (enExample) 2007-01-25

Family

ID=32511656

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2005502348A Pending JP2006514104A (ja) 2002-12-12 2003-12-11 グリコーゲンシンターゼキナーゼ−３阻害剤

Country Status (7)

Country Link
US (2) US7446092B2 (enExample)
EP (1) EP1569956B1 (enExample)
JP (1) JP2006514104A (enExample)
KR (1) KR20050091716A (enExample)
AU (1) AU2003286411A1 (enExample)
CA (1) CA2509374A1 (enExample)
WO (1) WO2004052404A2 (enExample)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008520649A (ja) * 2004-11-18 2008-06-19 テル アヴィヴ ユニヴァーシティ フューチャー テクノロジー ディヴェロップメント エル．ピー． グリコーゲンシンターゼキナーゼ−３阻害剤
JP2020502238A (ja) * 2016-12-23 2020-01-23 バイスクルアールディー・リミテッド 新規連結構造を有するペプチド誘導体
JP2020514403A (ja) * 2016-12-23 2020-05-21 バイスクルテクス・リミテッド Ｍｔ１−ｍｍｐに結合するためのペプチドリガンド
JP2021528432A (ja) * 2018-06-22 2021-10-21 バイスクルテクス・リミテッド Ｃｄ３８に結合するためのペプチドリガンド
JP2021528434A (ja) * 2018-06-22 2021-10-21 バイスクルテクス・リミテッド インテグリンαｖβ３に結合するためのペプチドリガンド
JP2022517399A (ja) * 2019-01-15 2022-03-08 バイスクルアールディー・リミテッド Ｃｄ３８に特異的な二環式ペプチドリガンド
US12049520B2 (en) 2017-08-04 2024-07-30 Bicycletx Limited Bicyclic peptide ligands specific for CD137
US12318454B2 (en) 2014-10-29 2025-06-03 Bicyclerd Limited Bicyclic peptide ligands specific for MT1-MMP
US12350343B2 (en) 2018-12-13 2025-07-08 Bicycletx Limited Bicyclic peptide ligands specific for MT1-MMP
US12378288B2 (en) 2018-02-23 2025-08-05 Bicycletx Limited Multimeric bicyclic peptide ligands
US12377155B2 (en) 2018-12-13 2025-08-05 Bicyclerd Limited Bicyclic peptide ligands specific for PSMA
US12435107B2 (en) 2019-07-30 2025-10-07 Bicycletx Limited Heterotandem bicyclic peptide complex
US12459974B2 (en) 2018-06-22 2025-11-04 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
US12491253B2 (en) 2018-12-13 2025-12-09 Bicyclerd Limited Bicyclic peptide ligands specific for MT1-MMP
US12492224B2 (en) 2018-12-21 2025-12-09 Bicycletx Limited Bicyclic peptide ligands specific for PD-L1

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2625201A (en) 2000-01-03 2001-07-16 Ramot University Authority For Applied Research And Industrial Development Ltd. Glycogen synthase kinase-3 inhibitors
US7378432B2 (en) * 2001-09-14 2008-05-27 Tel Aviv University Future Technology Development L.P. Glycogen synthase kinase-3 inhibitors
JP2006514104A (ja) * 2002-12-12 2006-04-27 テル アヴィヴ ユニヴァーシティ フューチャー テクノロジー ディヴェロップメント エル．ピー． グリコーゲンシンターゼキナーゼ−３阻害剤
EP2114397A4 (en) * 2006-12-20 2013-06-12 Medwell Lab Ltd NOVEL CONJUGATES OF POLY-UNSATURATED FATTY ACIDS WITH AMINES AND THERAPEUTIC USES THEREOF
WO2009154697A2 (en) 2008-05-28 2009-12-23 Massachusetts Institute Of Technology Disc-1 pathway activators in the control of neurogenesis
AU2008258150B1 (en) * 2008-12-16 2009-03-19 Jorge Miguel Pereira An Improved Knee Pad
WO2010098888A1 (en) * 2009-02-27 2010-09-02 Massachusetts Institute Of Technology Uses of chemicals to modulate gsk-3 signaling for treatment of bipolar disorder and other brain disorders
WO2012101599A2 (en) 2011-01-27 2012-08-02 Ramot At Tel-Aviv University Ltd. Glycogen synthase kinase-3 inhibitors
WO2012101601A1 (en) 2011-01-27 2012-08-02 Ramot At Tel-Aviv University Ltd. Glycogen synthase kinase-3 inhibitors
US9718859B2 (en) 2013-06-24 2017-08-01 Ramot At Tel-Aviv University Ltd. Glycogen synthase kinase-3 inhibitors
WO2015155738A2 (en) 2014-04-09 2015-10-15 Christopher Rudd Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001049709A1 (en) * 2000-01-03 2001-07-12 Ramot University Authority For Applied Research & Industrial Development Ltd. Glycogen synthase kinase-3 inhibitors

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1471621A (en) 1922-02-18 1923-10-23 Arthur W Mccord Soap-dispensing device
US2046068A (en) 1934-03-03 1936-06-30 Arthur W Gray Device for measuring materials
GB781806A (en) 1955-04-29 1957-08-28 Roche Products Ltd Organic phosphate, salts thereof, and process for the manufacture thereof
US3193159A (en) 1964-02-24 1965-07-06 Vernon E Swindler Dispenser for comminuted material and the like
US4186646A (en) 1973-08-17 1980-02-05 Martin Carl D Adjustable charging bar
RU2146262C1 (ru) 1993-06-30 2000-03-10 Фармация Энд Апджон С.П.А. Пептиды, способ их получения, фармацевтическая композиция и способ ее получения
US5861266A (en) 1994-02-28 1999-01-19 New York University Treatment of diabetes mellitus and insulin receptor signal transduction
US5462101A (en) 1994-07-05 1995-10-31 Mouchmouchian; Silva Baby feeding system
US5807718A (en) 1994-12-02 1998-09-15 The Scripps Research Institute Enzymatic DNA molecules
DE19524133A1 (de) 1995-07-03 1997-01-09 Bayer Ag Die Verwendung von neuen und bekannten kationischen 4,5-Dihydro-1H-1,2,3-triazoliumverbindungen als Farbstoffe, neue kationische 4,5-Dihydro-1H-1,2,3-triazoliumverbindungen und deren Herstellung
US5948765A (en) 1996-03-15 1999-09-07 Washington University Inhibition of intracellular signal transduction by 14-3-3-binding peptides
US6057117A (en) 1996-04-04 2000-05-02 Chiron Corporation Identification and use of selective inhibitors of glycogen synthase kinase 3
WO1997041854A1 (en) 1996-05-07 1997-11-13 The Trustees Of The University Of Pennsylvania Inhibitors of glycogen synthase kinase-3 and methods for identifying and using the same
US6077954A (en) 1996-08-01 2000-06-20 Isis Pharmaceuticals, Inc. Substituted heterocyclic compounds
AU4920397A (en) 1996-10-11 1998-05-11 Chiron Corporation Purine inhibitors of glycogen synthase kinase 3 (gsk3)
US6441140B1 (en) 1998-09-04 2002-08-27 Cell Signaling Technology, Inc. Production of motif-specific and context-independent antibodies using peptide libraries as antigens
JP2002535791A (ja) 1999-01-27 2002-10-22 エンバヤ インコーポレイテッド 三角形網目のプログレッシブ圧縮
US6495376B1 (en) 1999-02-18 2002-12-17 Beth Israel Deaconess Medical Center Methods and compositions for regulating protein-protein interactions
GB9906245D0 (en) 1999-03-19 1999-05-12 Medical Res Council Enzyme
IL133243A0 (en) 1999-03-30 2001-03-19 Univ Ramot A method and system for super resolution
IL130325A0 (en) 1999-06-07 2000-06-01 Yeda Res & Dev Pharmaceutical compositions comprising allicin
AU2001280229B2 (en) 2000-08-21 2006-12-07 Pacific Corporation Novel thiourea derivatives and the pharmaceutical compositions containing the same
AU2001287914A1 (en) 2000-09-22 2002-04-02 University Of Dundee The Protein kinase regulation
US7378432B2 (en) 2001-09-14 2008-05-27 Tel Aviv University Future Technology Development L.P. Glycogen synthase kinase-3 inhibitors
JP2006514104A (ja) 2002-12-12 2006-04-27 テル アヴィヴ ユニヴァーシティ フューチャー テクノロジー ディヴェロップメント エル．ピー． グリコーゲンシンターゼキナーゼ−３阻害剤
GB2396109B (en) 2002-12-12 2006-04-19 Johnson & Johnson Medical Ltd Absorbent multilayer hydrogel wound dressings
EP1638557A4 (en) 2003-06-27 2007-11-07 Univ Tel Aviv Future Tech Dev INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3
AU2005234687A1 (en) 2003-06-27 2005-12-08 Tel Aviv Universtiy Future Technology Development L.P. Glycogen Synthase Kinase-3 Inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001049709A1 (en) * 2000-01-03 2001-07-12 Ramot University Authority For Applied Research & Industrial Development Ltd. Glycogen synthase kinase-3 inhibitors

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008520649A (ja) * 2004-11-18 2008-06-19 テル アヴィヴ ユニヴァーシティ フューチャー テクノロジー ディヴェロップメント エル．ピー． グリコーゲンシンターゼキナーゼ−３阻害剤
US12318454B2 (en) 2014-10-29 2025-06-03 Bicyclerd Limited Bicyclic peptide ligands specific for MT1-MMP
JP2020502238A (ja) * 2016-12-23 2020-01-23 バイスクルアールディー・リミテッド 新規連結構造を有するペプチド誘導体
JP2020514403A (ja) * 2016-12-23 2020-05-21 バイスクルテクス・リミテッド Ｍｔ１−ｍｍｐに結合するためのペプチドリガンド
JP7387440B2 (ja) 2016-12-23 2023-11-28 バイスクルテクス・リミテッド Ｍｔ１－ｍｍｐに結合するためのペプチドリガンド
US12049520B2 (en) 2017-08-04 2024-07-30 Bicycletx Limited Bicyclic peptide ligands specific for CD137
US12378288B2 (en) 2018-02-23 2025-08-05 Bicycletx Limited Multimeric bicyclic peptide ligands
JP2021528434A (ja) * 2018-06-22 2021-10-21 バイスクルテクス・リミテッド インテグリンαｖβ３に結合するためのペプチドリガンド
JP2021528432A (ja) * 2018-06-22 2021-10-21 バイスクルテクス・リミテッド Ｃｄ３８に結合するためのペプチドリガンド
US12459974B2 (en) 2018-06-22 2025-11-04 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
US12350343B2 (en) 2018-12-13 2025-07-08 Bicycletx Limited Bicyclic peptide ligands specific for MT1-MMP
US12377155B2 (en) 2018-12-13 2025-08-05 Bicyclerd Limited Bicyclic peptide ligands specific for PSMA
US12491253B2 (en) 2018-12-13 2025-12-09 Bicyclerd Limited Bicyclic peptide ligands specific for MT1-MMP
US12492224B2 (en) 2018-12-21 2025-12-09 Bicycletx Limited Bicyclic peptide ligands specific for PD-L1
JP2022517399A (ja) * 2019-01-15 2022-03-08 バイスクルアールディー・リミテッド Ｃｄ３８に特異的な二環式ペプチドリガンド
US12435107B2 (en) 2019-07-30 2025-10-07 Bicycletx Limited Heterotandem bicyclic peptide complex

Also Published As

Publication number Publication date
WO2004052404A3 (en) 2004-07-29
EP1569956B1 (en) 2014-02-26
US20090062180A1 (en) 2009-03-05
AU2003286411A1 (en) 2004-06-30
US7446092B2 (en) 2008-11-04
US20060135408A1 (en) 2006-06-22
CA2509374A1 (en) 2004-06-24
EP1569956A2 (en) 2005-09-07
KR20050091716A (ko) 2005-09-15
WO2004052404A2 (en) 2004-06-24
US7833974B2 (en) 2010-11-16

Similar Documents

Publication Publication Date Title
JP2006514104A (ja) グリコーゲンシンターゼキナーゼ−３阻害剤
US9243034B2 (en) Glycogen synthase kinase-3 inhibitors
WO2001049709A1 (en) Glycogen synthase kinase-3 inhibitors
JP2007527859A (ja) グリコーゲンシンターゼキナーゼ−３阻害剤
Hauck et al. p21CIP1/WAF1-dependent inhibition of cardiac hypertrophy in response to Angiotensin II involves Akt/Myc and pRb signaling
US7378432B2 (en) Glycogen synthase kinase-3 inhibitors
US20250262329A1 (en) Treatment of heart disease by disruption of the anchoring of pp2a
US9688719B2 (en) Glycogen synthase kinase-3 inhibitors
JP4954888B2 (ja) グリコーゲンシンターゼキナーゼ−３阻害剤
JP4651617B2 (ja) Ｌｋｂ１リン酸化活性を検定する方法
CN111670048B (zh) 增强抗凋亡途径以预防dox毒性的方法
US9718859B2 (en) Glycogen synthase kinase-3 inhibitors
KR101215201B1 (ko) Ｘｉａｐ 단백질을 포함하는 허혈성 질환을 치료 또는 예방하기 위한 조성물
US9200333B2 (en) Methods for identifying modulators of murine double minute 2
HUP0401865A2 (hu) Protein-hisztidin-foszfatáz alkalmazása
US20170199199A1 (en) Compositions and Methods for Regulating Glucose Metabolism
WO2006075172A2 (en) Methods for identifying compounds capable of modulating cftr/ck2 interaction and/or cftr phosphorylation by ck2
WO2007039254A2 (en) Use of fusion proteins for the prevention or the treatment of pathologies resulting from ischemia
WO2009016384A2 (en) Gsk-3 inhibitors
WO2008098308A1 (en) Agents and methods for treatment of cell proliferative diseases and conditions

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061201

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061201

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100713

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110121